Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | BCR | P11274 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900391 | 0.86 | SMN1; SMN2 (0.43) | IDO1ALDH1A1LMNATACR1SMN1; SMN2 | |
| SCHEMBL18238945 | 0.80 | ABL1 (0.50) | ABL1ABCB1BCRIDO1ESR2 | |
| SCHEMBL21141090 | 0.79 | PDE4A (0.36) | ABL1ABCB1BCRMMP3BCL2L1 | |
| SCHEMBL21141091 | 0.79 | ESR2 (0.49) | IDO1ESR2ESR1ADORA2AADORA1 | |
| SCHEMBL14302570 | 0.78 | ABL1 (0.52) | ABL1ABCB1BCRESR2MMP3 | |
| SCHEMBL7608259 | 0.77 | GSTP1 (0.47) | ESR2ESR1ADORA2AADORA1 | |
| SCHEMBL18415207 | 0.76 | SMN1; SMN2 (0.46) | ABL1ABCB1BCRIDO1ESR2 | |
| SCHEMBL21141310 | 0.76 | ABL1 (0.46) | ABL1ABCB1BCRIDO1ESR2 | |
| SCHEMBL14310390 | 0.76 | ABL1 (0.50) | ABL1ABCB1BCRESR2MMP3 | |
| SCHEMBL21522574 | 0.74 | ALDH1A1 (0.52) | ALDH1A1CYP3A4LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | HCAR2, CHRM3, BDKRB2 | ABL1 4549/4885ABCB1 569/4885BCR 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.